News
A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...
Eli Lilly and Company (NYSE:LLY) stock fell on Thursday morning after the pharmaceutical giant’s diabetes drug Mounjaro ...
Eli Lilly's Mounjaro demonstrates significant cardiovascular benefits for Type 2 diabetes patients with heart disease, ...
While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase ...
Eli Lilly (LLY) has recently shared positive developments in its innovative therapies, reporting significant progress with Mounjaro and Kisunla in cardiovascular health and Alzheimer's treatment, ...
A hormone expert has explained why some people’s sex drive goes ‘through the roof’ while using Mounjaro. Use of the drug for ...
Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results